Search Results

CrystalGenomics, Inc. (KOSDAQ: 083790), a commercial stage biopharmaceutical company that is dedicated to the discovery, development and commercialization of novel therapeutics in unmet medical need areas of inflammation, oncology, and infectious disease, today announced the appointment of Gavin Choy, PharmD, MBA as President of CG Pharmaceuticals, Inc.,

CrystalGenomics, Inc. announced today that they have signed an Export Agreement with Apsen Farmacêutica for the commercialization of Acelex® (polmacoxib) in Brazil.

CrystalGenomics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of patients with pancreatic cancer.

CBT Pharmaceuticals (CBT) and CrystalGenomics, Inc., (KOSDAQ:083790) today announced a co-development agreement for an investigational combination therapy of CBT-501 and CG200745 across a variety of solid tumors with high unmet medical needs.